Targeted treatment of esophagogastric cancer

• Verfasst von: Kopp, Hans-Georg [VerfasserIn]
• Verfasst von: Hofheinz, Ralf-Dieter [VerfasserIn]
• Titel: Targeted treatment of esophagogastric cancer
• Verf.angabe: Hans-Georg Kopp, Ralf-Dieter Hofheinz
• E-Jahr: 2016
• Jahr: November 22, 2016
• Umfang: 7 S.
• Fussnoten: Gesehen am 07.02.2019
• Titel Quelle: Enthalten in: Oncology research and treatment
• Ort Quelle: Basel : Karger, 2014
• Jahr Quelle: 2016
• Band/Heft Quelle: 39(2016), 12, Seite 788-794
• ISSN Quelle: 2296-5262
• DOI: doi:10.1159/000452877
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1587376725

Abstract

Adenocarcinoma of the esophagogastric junction (EGJ) and stomach remains one of the most common causes of cancer-related death worldwide. Although there is increasing data on the mutational landscape of esophagogastric cancer, phase III trials often yield negative results, and there is a paucity of approved targeted agents. For the time being, the subset of patients carrying HER2-positive metastatic tumors can receive trastuzumab in addition to chemotherapy. Furthermore, ramucirumab has been found to be active both as a single agent and in combination with paclitaxel. Herein, we give an overview of currently approved targeted treatments for locally advanced/resectable as well as unresectable/metastatic EGJ/gastric adenocarcinoma, summarizing the underlying clinical studies. Moreover, further potential targets still under investigation are presented.